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Abstract The ability to self-replicate is a fundamental feature
of life, reflected at the cellular level by a highly regulated process
initiated in G1 phase via commitment to a round of DNA
replication and cell division. Here we briefly highlight recent
advances in understanding the molecular pathways which govern
the decision of mammalian somatic cells to enter S phase, and the
so-called cell cycle checkpoints which guard the G1/S transition
and S phase progression against potentially deleterious effects of
genotoxic stress. Particular emphasis is put on the emerging
parallel yet cooperative pathways of retinoblastoma protein
(pRB)^E2F and Myc, their convergence to control the activity of
the cyclin-dependent kinase 2 (Cdk2) at the G1/S boundary, as
well as the two waves of checkpoint responses at G1/S: the rapid
pathway(s) leading to Cdc25A degradation, and the delayed
p53^p21 cascade, both silencing the Cdk2 activity upon DNA
damage. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Many of the fate decisions of vertebrate somatic cells are
taken in the G1 phase of their cell division cycles. Key among
such decisions is the question whether or not the cell should
proliferate. When the cellular and tissue environments are
favourable and the cell does initiate its division cycle, then
tight surveillance mechanisms (cell cycle checkpoints) are
also imposed to monitor the order and quality of the cell cycle
events, with the option to halt the cell cycle at virtually any
transition point if a major malfunction or DNA damage are
encountered [1]. The necessity to carefully regulate both the
cell cycle machinery itself, and the cell cycle checkpoints is
apparent from the central role of these mechanisms in devel-
opment and homeostatic tissue renewal, and the fact that fail-
ure to execute these programmes in an error-free manner may
lead to devastating consequences such as cancer. The cell’s
commitment to replicate the genome and eventually divide
has been assigned to an operationally de¢ned period in late
G1, known as the restriction point, when the cell switches
from its mitogen-dependent growth in early G1, to a largely
growth factor-independent progression into, and beyond, S
phase. Considerable e¡orts in the cell cycle ¢eld have been
devoted to explain the restriction point switch in molecular
terms, mainly focusing on the retinoblastoma protein (pRB)
pathway as a candidate mechanism operating in G1 [2^5].
Recent evidence shows, however, that the RB pathway alone
can not account for the G1/S control, and evidence is mount-
ing to implicate the Myc proto-oncogene as a central element
of a pathway parallel to, and cooperating with, the pRB^E2F
axis [6^11]. Another type of dichotomy, reviewed here, en-
compasses the emerging basis of the so far elusive, rapid
and transient cell cycle checkpoint response at G1/S and in
S phase. This initial, acute phase of the G1/S checkpoint op-
erates via silencing Cdc25A (see Section 3.2), and it functions
independently of the known, more delayed and sustained G1
arrest due to stabilisation and transcriptional activation of the
p53 tumour suppressor [12,13]. Signi¢cantly, a feature shared
by all these pathways is their convergence on the control of
cyclin-dependent kinase 2 (Cdk2), a cyclin E- and A-depen-
dent G1/S kinase whose activity is rate-limiting and essential
for DNA replication.
2. Molecular pathways controlling G1/S transition
2.1. The RB^E2F pathway
The functions and regulation of the p16^cyclin D^Cdk4(6)^
pRB^E2F cascade, known as the RB pathway, have been
reviewed thoroughly in recent years [2^5,14], and here we
only address the most recent novel information about this
key G1/S controlling mechanism. The growth-suppressive,
underphosphorylated form of the pRB ‘pocket protein’ pre-
vents premature entry into S phase by binding to a number of
cellular proteins such as the transcription factors E2F-1^5
which regulate expression of S phase genes. Phosphorylation
of a host of pRB’s serine and threonine residues in mid-to-late
G1 by mitogen-induced cyclin D-dependent kinases cancels
the growth-inhibitory e¡ects of pRB, thereby allowing activa-
tion of a plethora of cell cycle regulatory genes including
those for cyclins E and A. Novel insights have been obtained
into the mechanistic aspects of gene expression control via
pRB^E2F, such as the roles of local chromatin remodeling
through pRB-bound histone deacetylase, E2F acetylation,
and the relative balance between direct inhibition of E2F ac-
tivity by pRB versus active repression of transcription by the
pRB^E2F complex [14]. Exploration of non-phosphorylat-
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able, constitutively active mutants of pRB revealed some
unexpected functions of pRB even in the S/G2/M phases of
the cell cycle, such as centrosome duplication, or stabilisation
of mitotic regulators [15^17]. Together with some conditions
when endogenous pRB becomes activated in post-G1 phases
of the cell cycle [18,19], these ¢ndings indicate why it is critical
for cycling cells to maintain pRB in its phosphorylated state
(through cyclin E^Cdk2 and cyclin A^Cdk2 activities) from
late G1 until mitosis. Most relevant to the focus of this re-
view, the ability of mammalian cells to eventually escape a G1
arrest imposed by such constitutively active mutant pRB
strongly suggested the existence of another, pRB^E2F-inde-
pendent mechanism allowing entry into S phase ([6] and Sec-
tions 2.2 and 2.3). Although not commonly regarded as a
component of the RB pathway, the pRB-related p130 is the
major pocket protein which inhibits E2F in quiescent cells,
and it becomes phosphorylated during the G0^G1^S traverse
with kinetics similar to that of pRB phosphorylation. Recent
identi¢cation of 22 phosphorylation sites of p130 targeted in
vivo by combined activities of cyclin D^Cdk4, cyclin E^Cdk2
and non-Cdk kinases [20] shows only a surprisingly limited
analogy with regulation of pRB. The ability of a phosphory-
lation-de¢cient p130 mutant to impose a sustained G1 block,
considerably more powerful than the e¡ect of analogous mu-
tant pRB, along with the recently identi¢ed cancer-associated
p130 mutations, qualify p130 as a candidate tumour suppres-
sor ([20] and references therein). Another incentive to under-
stand p130 stems from the experiments with cells genetically
de¢cient in p130 and p107, the third pocket protein. These
p130/p107 double-de¢cient cells are resistant to p16-mediated
G1 arrest, analogous to cells de¢cient in pRB, thus implying
that in addition to pRB, the p130/p107 pocket proteins also
provide an essential regulatory function in G1 [21]. While
p107 becomes expressed only later during the cell cycle,
p130 operates throughout G0^S phase progression, and we
suggest that at least p130 should also be adopted as a com-
ponent of the RB pathway, as schematically outlined in the
relevant part of Fig. 1.
2.2. The role of Myc in regulation of G1/S transition
The c-myc proto-oncogene is a transcription factor of the
helix^loop^helix/leucine zipper protein family, whose endoge-
nous expression is promptly induced by mitogens and whose
ectopic expression, like that of E2F [22,23] or cyclin E^Cdk2
[24], is able to induce entry into S phase in quiescent cells [25].
Despite the generally accepted role of Myc in promoting pro-
liferation, the identity of its target genes which mediate the
mitogenic e¡ects, and the mechanistic links of Myc with the
cell cycle machinery including the RB pathway are only very
recently coming to light. Among the downstream target genes
of Myc, relevant for G1/S control, are those encoding cyclins
D2, D1 and E, and the Cdc25A phosphatase, an essential
regulator of S phase entry which strips Cdk2 of its inhibitory
phosphates on Tyr 15/Thr 14 ([6] and references therein,
[26,27]). In terms of the key activities or mitogenic processes,
c-myc has been implicated in at least three distinct, and ge-
netically separable, programmes: regulation of cyclin E^Cdk2
activity, E2F-dependent transcription, and cell growth (i.e. an
increase in cell mass) [9,25,28]. The positive e¡ect of Myc on
cell growth is becoming apparent from work with both Dro-
sophila and mammalian cells [25,28], and from the identity of
putative target genes of Myc, a subset of which promote me-
tabolism, in particular protein translation [29,30]. Arguably
the best studied of the Myc-induced proliferation-promoting
programmes is the activation of cyclin E^Cdk2 kinase. This
complex programme apparently includes direct transcriptional
e¡ects on cyclin E and Cdc25A expression, and indirect mech-
anisms such as sequestration of the Cdk inhibitor p27kip1 into
cyclin D^Cdk4(6) complexes away from cyclin E^Cdk2, and
phosphorylation and subsequent ubiquitination and protea-
some-mediated degradation of the p27kip1 protein at G1/S
[6,7,26,27,31,32].
Fig. 1. Cyclin E^Cdk2 as a nodal point integrating signals from the G1/S-promoting pathways. Cyclin E^Cdk2 stimulates DNA synthesis pre-
sumably by facilitating origin ¢ring through Cdc45-dependent loading of DNA polymerase K and promoting histone biosynthesis through direct
phosphorylation of NPAT, a factor required for histone transcription. In addition, cyclin E^Cdk2, once activated, ampli¢es the signals from
the mitogen-induced G1/S-promoting pathways by phosphorylating and inactivating the E2F repressors pRB and p130, and by targeting the
p27 CDK inhibitor for ubiquitination and rapid proteasome-mediated destruction.
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Recent construction of a mutant known as MadMyc capa-
ble of actively repressing c-myc target genes [8], allowed ex-
amination of cellular e¡ects upon both short-term [8,9] and
long-term [6] silencing of endogenous Myc. Transient expres-
sion of MadMyc causes G1 arrest independent of functional
pRB [8,10], yet mitogen-stimulated cells exposed to MadMyc
in long-term experiments eventually enter S phase despite the
lack of Myc-mediated transcription [6]. These and other data
can be reconciled by a concept of two parallel and cooperat-
ing G1/S-governing pathways, regulated by pRB^E2F and
Myc, respectively (Fig. 1). While silencing of either cascade
only delays but does not completely block entry into S phase,
cells with concomitantly silenced E2F and Myc are unable to
initiate DNA synthesis despite the presence of growth factors
[6]. Not surprisingly, a signi¢cant functional cross-talk also
exists between these parallel RB^E2F and Myc pathways,
for instance through Myc-mediated transcriptional activation
of E2F-2, E2F-3 and Id2, three transcriptional regulators of
G1/S negatively controlled by pRB [33^35]. Despite their
links, however, either the E2F- or the Myc-induced pro-
grammes appear su⁄ciently powerful to drive mammalian
cells into S phase, possibly re£ecting the fact that either path-
way can induce cyclin E^Cdk2 and/or cyclin A^Cdk2 activity
(Fig. 1 and Section 2.3). On the other hand, cells selectively
deprived of either E2F or Myc activity are unable to reach
mitosis [6,9,10,17], strongly suggesting that activities of both
the RB and Myc pathways are required for the timely pro-
gression through, and successful completion of, the cell divi-
sion cycle, and thus for continuous proliferation of mamma-
lian somatic cells.
2.3. Cyclin E^Cdk2 as a convergence point of G1/S control
Thus, the concept which is emerging from these new dis-
coveries on the role of the RB^E2F and Myc cascades is the
one of two parallel, cooperating and interacting pathways,
each targeting a number of downstream genes and cellular
functions. A striking feature, also of central importance for
this review, is the convergence of both the RB^E2F- and Myc-
regulated programmes on the control of abundance and ac-
tivity of cyclin E^Cdk2, a key G1/S-promoting enzyme which
is both rate-limiting and essential for S phase entry [3,4]. This
concept is also supported by the ability of ectopically ex-
pressed cyclin E and Cdc25A to synergistically rescue the
concomitant blockade of both the pRB^E2F and Myc path-
ways, consistent with cyclin E^Cdk2 inducing DNA synthesis
downstream of E2F and Myc [6]. The multiple ways through
which Myc stimulates cyclin E^Cdk2 are listed in Section 2.2,
and E2F contributes to the timely expression and activation
of this key S phase-promoting kinase by transcriptional in-
duction of genes for cyclin E and Cdc25A ([14,36], and refer-
ences therein).
A fundamental question which follows the realisation of
the central role of cyclin E^Cdk2 in the regulation of G1/S
transition is the issue of the underlying molecular mecha-
nisms and, thus, the identity of the key physiological
substrates phosphorylated by cyclin E^Cdk2. Probably the
best known substrate of cyclin E^Cdk2 is pRB and its re-
lated pocket proteins p130 and p107 [2^5,14,20]. Cdk2 ac-
tivity appears to complete and maintain the neutralising
phosphorylation of pRB, a process initiated by cyclin D-
dependent kinases in G1, thereby preventing unscheduled
activation of pRB in S phase, and feeding a regulatory
loop which ampli¢es both E2F and cyclin E^Cdk2 activity
(Fig. 1).
Another established target of the cyclin E^Cdk2 kinase is
p27kip1, whose phosphorylation and subsequent degradation
allows the timely elevation of Cdk2 activity necessary for S
phase initiation and progression ([31,37], Fig. 1). However,
neither of these substrates can account for the powerful S
phase-promoting e¡ect of cyclin E^Cdk2 activity in cells ar-
rested in G1 by the non-phosphorylatable pRB [38], clearly
indicating that other important substrates of this kinase must
exist at G1/S. Two recently identi¢ed candidate substrates
may explain the so far elusive roles of cyclin E^Cdk2 in his-
tone biosynthesis and initiation of DNA replication. Histones
are components of nucleosomes, and must be provided during
DNA replication, through a process partly controlled by ele-
vated transcription of the histone genes. Recently, the
p220NPAT protein was identi¢ed as a substrate associated
with, and phosphorylated by, the cyclin E^Cdk2 kinase. In
addition, such modi¢cation by cyclin E^Cdk2 was shown to
be essential for the ability of p220NPAT to cyclically activate
the histone gene promoters at the onset of S phase (Fig. 1;
[39^41]). Finally, while the licensing of replication origins via
sequential binding of the origin recognition complex, Cdc6,
and the MCM family of proteins probably does not require
cyclin E^Cdk2, the actual ¢ring of the licensed origins appears
dependent on loading of Cdc45 which is dependent on Cdk
activity and essential for subsequent recruitment of DNA
polymerase K into the pre-initiation complex [42^44].
Although other relevant substrates of cyclin E^Cdk2 may
well be discovered, the cyclin E^Cdk2-dependent functions
of Cdc45 and p220NPAT in the critical steps required for
successful DNA replication may provide the long-sought in-
sight into the physiological role of cyclin E^Cdk2 in G1/S
control (Fig. 1).
Apart from its essential function in cell proliferation, the
strategic role of cyclin E^Cdk2 at the G1/S transition makes
this kinase a candidate downstream target of the cell cycle
checkpoint responses to DNA damage, a topic which is ad-
dressed in the following sections of this review.
3. DNA damage response pathways at G1/S
3.1. The p53^p21 axis
When the genetic material is damaged, a delay in cell cycle
progression facilitates DNA repair, thereby avoiding the rep-
lication and subsequent propagation of potentially hazardous
mutations. The ability of the cell cycle checkpoints, signalling
pathways which monitor the integrity and replication status of
the genome, to inhibit entry into S phase is intimately asso-
ciated with the function of the p53 tumour suppressor [12].
The p53 protein is a transcription factor which becomes sta-
bilised and active upon DNA damage, and in turn regulates
transcription of a large number of genes, among them the
p21Waf1=Cip1 Cdk inhibitor capable of silencing the Cdks which
are essential for S phase entry [4,12]. Rapid advances in the
DNA damage ¢eld have recently provided some novel insights
into the molecular mechanics of the p53 pathway, particularly
the upstream elements of the cascade(s) which eventually
modify p53. The emerging scenario indicates an early activa-
tion (within a few minutes after DNA damage) of ataxia
telangiectasia mutated (ATM) or ataxia telangiectasia related
(ATR) (the choice between the two depending on the precise
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nature of the DNA lesion), two large kinases from the PI-3
kinase superfamily [1,13]. ATM/ATR then phosphorylate a
range of substrates, including p53 (on serine 15) and the
checkpoint kinases Chk2 and Chk1 (again dependent on the
type of damage) which become activated and subsequently
propagate the signal to downstream e¡ectors [1,13]. Recent
data [45^47] show that activated Chk2 and Chk1 phosphory-
late p53 on serine 20, an event which leads to decreased pro-
tein turnover and thus accumulation of p53 (Fig. 2). The high
lability of the p53 protein in non-damaged cells depends on
Mdm2, which binds to the N-terminus of p53 around Ser20
and targets p53 for ubiquitination and proteasome-mediated
degradation. Phosphorylation of Ser20 prevents e⁄cient inter-
action of p53 with Mdm2 and appears essential for stabilisa-
tion of p53 after DNA damage, but other modi¢cations of
p53 itself and phosphorylation of Mdm2 by the ATM/ATR
and Chk1/Chk2 kinases are likely to be involved as well
[13,48,49]. Mdm2 is itself transcriptionally activated by p53,
thereby creating a negative feedback loop with p53, and this
interplay is further complicated by the accompanying dynamic
changes of their subcellular localisation [12,50]. The nuclear
import and export of p53 may depend on its modi¢cations,
and it has very recently been shown that p53 uses its N-ter-
minus to interact with the microtubules and exploit these mo-
tors to aid its nuclear localisation [51]. Stabilised and acti-
vated p53 a¡ects the transcription of many genes, and
ongoing e¡orts to assess this response globally using the func-
tional genomic approaches may soon answer whether or not
the p53-induced Cdk inhibitor p21Waf1=Cip1 is the only critical
target downstream of p53 (Fig. 2) required to block the cell
cycle machinery in G1 in response to DNA damage [12].
3.2. The rapid response via Cdc25A degradation
Not all aspects of the G1 checkpoint responses to genotoxic
stress can be attributed to the p53 pathway, however, since at
least transient inhibition of Cdk2 in response to DNA damage
occurs even in cells lacking p53 or p21 [13,48]. In addition,
cells can also reduce the rate of ongoing DNA synthesis when
exposed to DNA damage, and this so-called intra-S phase
checkpoint is known to operate in an ATM-dependent, yet
p53/p21-independent manner [13]. Reports published within
the last several months now suggest that pathways targeting
the Cdc25A phosphatase may underlie the molecular events
which account for the p53-independent delay of G1/S transi-
tion, and likely also the transient intra-S phase checkpoint
responses [52^54]. Thus, regardless of the status of p53, the
total cellular activity of the Cdc25A phosphatase becomes
rapidly decreased when mammalian cells are exposed to UV
light or Q radiation, re£ecting DNA damage-induced ubiquiti-
nation and accelerated turnover of the Cdc25A protein by
proteasome [52]. This novel checkpoint pathway (Fig. 2) re-
sults in persistent inhibitory phosphorylation of Cdk2 on Thr
14/Tyr 15, and thus inhibition of cyclin E^Cdk2 and cyclin
A^Cdk2 kinases and G1/S arrest. Both the involvement of
Fig. 2. Cyclin E^Cdk2 integrates checkpoint pathways inducing both rapid and delayed G1/S responses to acute genotoxic stress. DNA damage
induced kinase cascades involving ATR/ATM and Chk1/Chk2 target Cdc25A for rapid ubiquitin/proteasome-mediated proteolysis. This event,
independent of transcription and de-novo protein synthesis culminates in a rapid inhibition of the S phase-promoting cyclin E^Cdk2 activity
through ‘locking’ it in an inactive, Thr 14- and Tyr 15-phosphorylated state. Activation of the delayed p53-mediated response, on the other
hand, requires Chk1/Chk2-dependent stabilisation of p53 itself before it can fully support de-novo synthesis of the p21 CDK inhibitor. In some
instances, accumulation of p21 to the threshold su⁄cient for sustained inhibition of cyclin E^Cdk2 lags behind the Cdc25A-mediated pathway
for several hours. As indicated, multiple components of both rapid and delayed mechanisms leading to cyclin E^Cdk2 inhibition in response
to DNA damage are deregulated in cancer, either by loss-of-function mutations (*), or by accumulation of the (proto)-oncogenic e¡ector
proteins (4).
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upstream checkpoint kinases such as Chk1 in this pathway,
and the fact that enhanced DNA damage and decreased cell
survival follow overexpression of Cdc25A which prevents its
downmodulation after genotoxic stress, are consistent with
this mechanism as a bona ¢de cell cycle checkpoint [52]. Fur-
ther supporting the emerging role of Cdc25A in mediating the
G1/S and S phase checkpoint responses (Fig. 2), Cdc25A be-
comes rapidly ubiquitinated and degraded in response to in-
complete DNA replication in mammalian cells [53], and in a
cell-free model of Xenopus egg extracts, the silenced activity of
Cdc25A and increased inhibitory phosphorylation of Cdk2
appear instrumental in imposing a checkpoint response to
DNA double-strand breaks [54].
3.3. The two-wave checkpoint response at G1/S
Collectively, these recent ¢ndings support a concept of two
successive waves of cell cycle checkpoint responses at G1/S
(Fig. 2). The initial, transient response is very rapid, leading
to the inhibition of Cdk2 within 20^30 min, and lasting for
only several hours [13,52]. This prompt cell cycle delay is
independent of p53 and transcription, and re£ects the cascade
operating via Cdc25A phosphorylation and degradation, and
thus silencing of Cdk2 due to its inhibitory phosphorylation
(see Section 3.2). It seems that this early response ¢ts well the
purpose of temporarily slowing down the cell cycle progres-
sion to provide more time for DNA repair. The second, de-
layed and considerably more sustained response is carried out
by the classical p53/p21 cascade. As the multistep process of
p53 modi¢cation, accumulation, activation and above all
transcriptional induction of the e¡ectors such as p21 requires
several hours, this wave of the G1/S checkpoint response is
better suited for long-term, and possibly even permanent,
elimination of cells whose DNA has been severely damaged
[48]. This possibility is also supported by the ability of the p53
pathway to induce apoptosis, another e⁄cient way to remove
hazardous, genetically damaged cells from the population. On
the other hand, the initial signalling events through ATM/
ATR and Chk1/Chk2 kinases appear to be shared and per-
formed in parallel to target both the early and the late
branches of the G1/S checkpoint responses (Fig. 2), and it
remains to be seen whether these two waves can ever occur
independently in cells pro¢cient in either cascade. The latter
point is highly relevant to the currently somewhat controver-
sial issue as to what extent the normal mammalian cells with
the activated p53 pathway are actually able to recover from
this sustained arrest [48,55]. It has also been suggested, that in
those cell types expressing cyclin D1, degradation of this cy-
clin might contribute to the more rapid, p53-independent re-
sponse to DNA damage in G1, apparently even independently
of the upstream checkpoint kinases such as ATM [56]. Despite
the time divergence and distinct intermediates of the two ma-
jor waves of cell cycle checkpoint responses at G1/S, the fea-
ture which uni¢es the p53-independent as well as p53-regu-
lated pathways is their ultimate convergence on silencing the
activity of Cdk2, the key e¡ector of both the mitogenic cas-
cades (see Section 2) and the safeguard mechanisms protecting
our cells against genotoxic stress (Figs. 1 and 2).
3.4. Defects in G1/S checkpoints, genomic instability and
cancer
Deregulated cell proliferation and genetic instability are
among the hallmarks of cancer, re£ecting defects in cell cycle
control, and aberrations in genome integrity checkpoints and
DNA repair machinery, respectively. Both the RB and Myc
pathways governing G1/S transition (see Section 2) are com-
monly targeted in oncogenesis, and this ¢eld has been re-
viewed repeatedly [5,57]. Here we will brie£y discuss the can-
cer-predisposing aberrations of the two-wave cell cycle
checkpoint response to DNA damage at G1/S, described in
Sections 3.1^3.3 and Fig. 2 (where the pathway components
which qualify as oncogenes or tumour suppressors are
marked). The most common of these defects are those of
the p53 tumour suppressor, either deletions or mutations tar-
geting di¡erent regions of the p53 gene itself, or the immediate
regulators of p53 including the Mdm2 proto-oncogene [12].
Mutations of the p53 gene can also be inherited, such as those
predisposing to cancers in diverse organs characteristic of a
subset of families with the Li^Fraumeni syndrome. Interest-
ingly, some of the Li^Fraumeni families which do not have
germ line mutations of p53 were shown to carry mutations in
the gene encoding the Chk2 kinase upstream of p53 in the
DNA response pathway ([58], Fig. 2), and occasional sporadic
cancer-associated mutations have been detected in both the
Chk1 and Chk2 genes [58^60]. Even defects at the very top
of the checkpoint cascade, namely mutations of the ATM
gene, predispose to cancer and a¡ect the outcome of tumour
therapy, in this case particularly the response to radiation [13].
The central component of the rapid G1/S checkpoint path-
way, the Cdc25A phosphatase, quali¢es as proto-oncogene
based on its ability to transform cells in culture and its over-
expression in several types of human tumours including car-
cinomas of the lung, breast and head and neck, where its
aberrant elevation correlates with poor prognosis [61^64]. Fi-
nally, cyclin E, the activatory subunit of the Cdk2 kinase and
a downstream e¡ector targeted by both the rapid and the
delayed wave of the G1/S checkpoint response, is a proto-
oncogene ampli¢ed and/or overexpressed in several types of
cancer, and its elevation may both deregulate cell cycle pro-
gression and contribute to genomic instability ([65] and refer-
ences therein).
4. Concluding remarks
Many fundamental phenomena in biology come in pairs,
such as the two strings of nucleotides carrying the blueprint
of life in the DNA double helix, to name just the most noto-
rious example. Here we provide some new examples of dichot-
omy in basic biological processes, by presenting the emerging
evidence for dual control pathways to govern both the G1/S
transition in cycling cells, and the response at G1/S to geno-
toxic stress. This short review should be regarded as an at-
tempt to help establish a conceptual framework for G1/S
transition as a critical period of the cell division cycle, and
to inspire further quests for a better explanation of why our
cells make the decision to proliferate the way they do. It is our
hope that the rapidly accumulating knowledge in this ¢eld will
also aid in developing more rational cancer treatment strat-
egies in the near future, as exempli¢ed by attempts to develop
clinically applicable Cdk inhibitors [66], search for attenuators
of checkpoint kinases which might presensitise cancer cells to
existing chemotherapy and radiotherapy regimens [67^69], or
design activators of the p53 function, either to stimulate wild-
type p53 or to re-vitalise its overabundant mutant forms
present in many human malignancies [12,70].
FEBS 24564 14-2-01
J. Bartek, J. Lukas/FEBS Letters 490 (2001) 117^122 121
Acknowledgements: The authors are grateful to the Danish Cancer
Society, the Danish Medical Research Council, and the Human Fron-
tier Science Programme for generous ¢nancial support, and apologise
to those whose data have been cited indirectly.
References
[1] Zhou, B.-B.S. and Elledge, S.J. (2000) Nature 408, 433^439.
[2] Weinberg, R.A. (1995) Cell 81, 323^330.
[3] Bartek, J., Bartkova, J. and Lukas, J. (1996) Curr. Opin. Cell.
Biol. 8, 805^814.
[4] Sherr, C. and Roberts, J.M. (1999) Genes Dev. 13, 1501^1512.
[5] Sherr, C. (2000) Cancer Res. 60, 3689^3695.
[6] Santoni-Rugiu, E., Falck, J., Mailand, N., Bartek, J. and Lukas,
J. (2000) Mol. Cell. Biol. 20, 3497^3509.
[7] Leone, G., DeGregori, J., Sears, R., Jakoi, L. and Nevins, J.R.
(1997) Nature 387, 422^426.
[8] Berns, K., Hijmans, E.M. and Bernards, R. (1997) Oncogene 15,
1347^1356.
[9] Beier, R. et al. (2000) EMBO J. 19, 5813^5823.
[10] Berns, K., Martins, C., Dannenberg, J.-H., Berns, A., te Riele, H.
and Bernards, R. (2000) Oncogene 19, 4822^4827.
[11] Roussel, M.F., Theodoras, A.M., Pagano, M. and Sherr, C.J.
(1995) Proc. Natl. Acad. Sci. USA 92, 6837^6841.
[12] Vogelstein, B., Lane, D. and Levine, A.J. (2000) Nature 408,
307^310.
[13] Rotman, G. and Shiloh, Y. (1999) Oncogene 18, 6135^6144.
[14] Harbour, J.W. and Dean, D.C. (2000) Genes Dev. 14, 2393^
2409.
[15] Lukas, C., SÖrensen, C.S., Kramer, E., Santoni-Rugiu, E., Lin-
deneg, C., Peters, J.-M., Bartek, J. and Lukas, J. (1999) Nature
401, 815^818.
[16] Meraldi, P., Lukas, J., Fry, A.M., Bartek, J. and Nigg, E. (1999)
Nat. Cell Biol. 1, 88^93.
[17] Chew, Y.P., Ellis, M., Wilkie, S. and Mittnacht, S. (1999) Onco-
gene 17, 2177^2186.
[18] Knudsen, K.E., Booth, D., Naderi, S., Sever-Chroneos, Z., Fri-
bourg, A.F., Hunton, I.C., Feramisco, J.R., Wang, J.Y. and
Knudsen, E.S. (2000) Mol. Cell. Biol. 20, 7751^7763.
[19] Saudan, P., Vlach, J. and Beard, P. (2000) EMBO J. 19, 4351^
4361.
[20] Hansen, K., Farkas, T., Lukas, J., Holm, K. Ro«nnstrand, L. and
Bartek, J. (2001) EMBO J., 20, in press.
[21] Bruce, J.L., Robert, K., Hurford Jr., R.K., Classon, M., Koh, J.
and Dyson, N. (2000) Mol. Cell. 6, 737^742.
[22] Johnson, D.G., Schwarz, J.K., Cress, W.D. and Nevins, J.R.
(1993) Nature 365, 349^352.
[23] Lukas, J., Petersen, B.O., Holm, K., Bartek, J. and Helin, K.
(1996) Mol. Cell. Biol. 16, 1047^1057.
[24] Connell-Crowley, L., Elledge, S.J. and Harper, J.W. (1998) Curr.
Biol. 8, 65^68.
[25] Bouchard, C., Staller, P. and Eilers, M. (1998) Trends Cell Biol.
8, 202^206.
[26] Bouchard, C. et al. (1999) EMBO J. 18, 5321^5333.
[27] Perez-Roger, I., Kim, S.H., Gri⁄ths, B., Sewing, A. and Land,
H. (1999) EMBO J. 18, 5310^5320.
[28] Elend, M. and Eilers, M. (1999) Curr. Biol. 9, R936^R938.
[29] Coller, H.A., Grandori, C., Tamayo, P., Colbert, T., Lander,
E.S., Eisenman, R.N. and Golub, T.R. (2000) Proc. Natl.
Acad. Sci. USA 97, 3260^3265.
[30] O’Hagan, R.C. et al. (2000) Nat. Genet. 24, 113^119.
[31] Montagnoli, A., Fiore, F., Eytan, E., Carrano, A.C., Draetta,
G.F., Hershko, A. and Pagano, M. (1999) Genes Dev. 13,
1181^1189.
[32] Alevizopoulos, K., Vlach, J., Hennecke, S. and Amati, B. (1997)
EMBO J. 16, 5322^5333.
[33] Adams, M.R., Sears, R., Nuckolls, F., Leone, G. and Nevins,
J.R. (2000) Mol. Cell. Biol. 20, 3633^3639.
[34] Sears, R., Ohtani, K. and Nevins, J.R. (1997) Mol. Cell. Biol. 17,
5227^5235.
[35] Lasorella, A., Noseda, M., Beyna, M. and Iavarone, A. (2000)
Nature 407, 592^598.
[36] Vigo, E., Mu«ller, H., Prosperini, E., Hateboer, G., Cartwright,
P., Moroni, M.C. and Helin, K. (1999) Mol. Cell. Biol. 19, 6379^
6395.
[37] Shea¡, R.J., Groudine, M., Gordon, M., Roberts, J.M. and Clur-
man, B.E. (1997) Genes Dev. 11, 1464^1478.
[38] Lukas, J., Herzinger, T., Hansen, K., Moroni, M.C., Resnitzky,
D., Helin, K., Reed, S.I. and Bartek, J. (1997) Genes Dev. 11,
1479^1492.
[39] Ma, T. et al. (2000) Genes Dev. 14, 2298^2313.
[40] Zhao, J., Kennedy, B.K., Lawrence, B.D., Barbie, D.A., Matera,
A.G., Fletcher, J.A. and Harlow, E. (2000) Genes Dev. 14, 2283^
2297.
[41] Zhao, J., Dynlacht, B., Imai, T., Hori, T. and Harlow, E. (1998)
Genes Dev. 12, 456^461.
[42] Jares, P. and Blow, J.J. (2000) Genes Dev. 14, 1528^1540.
[43] Arata, Y., Fujita, M., Ohtani, K., Kijima, S. and Kato, J.Y.
(2000) J. Biol. Chem. 275, 6337^6345.
[44] Zou, L. and Stillman, B. (1998) Science 280, 593^596.
[45] Hirao, A., Kong, Y.-Y., Matsuoka, A., Wakeham, A., Ruland,
J., Yoshida, H., Liu, D., Elledge, S.J. and Mak, T.W. (2000)
Science 287, 1824^1827.
[46] Chehab, N.H., Malikzay, A., Appel, M. and Halazonetis, T.D.
(2000) Genes Dev. 14, 278^288.
[47] Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y. and Prives, C. (2000)
Genes Dev. 14, 289^300.
[48] Carr, A.M. (2000) Science 287, 1765^1766.
[49] Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y. and
Shkedy, D. (1999) Proc. Natl. Acad. Sci. USA 96, 14973^14977.
[50] Vousden, K.H. and Vande Woude, G.F. (2000) Nat. Cell Biol. 2,
E178^E180.
[51] Giannakakou, P., Sackett, D.L., Ward, Y., Blagosklonny, M.
and Fojo, T. (2000) Nat. Cell Biol. 2, 709^717.
[52] Mailand, N., Falck, J., Lukas, C., Syljuafisen, R.G., Welcker, M.,
Bartek, J. and Lukas, J. (2000) Science 288, 1425^1429.
[53] Molinari, M., Mercurio, C., Dominquez, J., Goubin, F. and
Draetta, G.F. (2000) EMBO Rep. 1, 71^79.
[54] Costanzo, V., Robertson, K., Ying, C.Y., Kim, E., Avvedimento,
E., Gottesman, M. and Grieco, D. (2000) J. Mol. Cell. 6, 649^
659.
[55] Di Leonardo, A., Linke, S.P., Clarkin, K. and Wahl, G.M.
(1994) Genes Dev. 8, 2540^2551.
[56] Agami, R. and Bernards, R. (2000) Cell 102, 55^66.
[57] Hanahan, D. and Weinberg, R.A. (2000) Cell 100, 57^70.
[58] Bell, D.W. et al. (1999) Science 286, 2528^2531.
[59] Haruki, N., Saito, H., Tatematsu, Y., Konishi, H., Harano, T.,
Masuda, A., Osada, H., Fujii, Y. and Takahashi, T. (2000) Can-
cer Res. 60, 4689^4692.
[60] Bertoni, F., Codegoni, A.M., Furlan, D., Tibiletti, M.G., Capel-
la, D. and Broggini, M. (1999) Genes Chromosomes Cancer 26,
176^180.
[61] Cangi, M.G., Cukor, B., Soung, P., Signoretti, S., Moreira Jr.,
G., Ranashinge, M., Cady, B., Pagano, M. and Loda, M. (2000)
J. Clin. Invest. 106, 753^761.
[62] Galaktionov, K., Lee, A.K., Eckstein, J., Draetta, G., Meckler,
J., Loda, M. and Beach, D. (1995) Science 269, 1575^1577.
[63] Gasparotto, D., Maestro, R., Piccinin, S., Vukosavljevic, T., Bar-
zan, L., Sulfaro, S. and Boiocchi, M. (1997) Cancer Res. 57,
2366^2368.
[64] Wu, W., Fan, Y.H., Kemp, B.L., Walsh, G. and Mao, L. (1998)
Cancer Res. 58, 4082^4085.
[65] Spruck, C.H., Won, K.A. and Reed, S.I. (1999) Nature 401, 297^
300.
[66] Garrett, M.D. and Fattaey, A. (1999) Curr. Opin. Genet. Dev. 9,
104^111.
[67] Jackson, J.R., Gilmartin, A., Imburgia, C., Winkler, J.D., Mar-
shall, L.A. and Roshak, A. (2000) Cancer Res. 60, 566^572.
[68] Busby, E.C., Leistritz, D.F., Abraham, R.T., Karnitz, L.M. and
Sarkaria, J.N. (2000) Cancer Res. 60, 2108^2112.
[69] Graves, P.R., Yu, L., Schwarz, J.K., Gales, J., Sausville, E.A.,
O’Connor, P.M. and Piwnica-Worms, H. (2000) J. Biol. Chem.
275, 5600^5605.
[70] Selivanova, G., Kawasaki, T., Ryabchenko, L. and Wiman, K.G.
(1998) Semin. Cancer Biol. 8, 369^378.
FEBS 24564 14-2-01
J. Bartek, J. Lukas/FEBS Letters 490 (2001) 117^122122
